High-sensitive troponin T in chronic heart failure correlates with severity of symptoms, left ventricular dysfunction and prognosis independently from N-terminal pro-b-type natriuretic peptide
Authors:
- Carsten G. JungbauerCJCarsten G. Jungbauer
- Julia RiedlingerJRJulia Riedlinger
- Stefan BuchnerSBStefan Buchner
- Christoph BirnerCBChristoph Birner
- Markus ReschMRMarkus Resch
- Matthias LubnowMLMatthias Lubnow
- Kurt DeblKDKurt Debl
- Monika BuesingMBMonika Buesing
- Hendrik HuedigHHHendrik Huedig
- Günter RieggerGRGünter Riegger
- Andreas LuchnerALAndreas Luchner
- 1 January 2011
- journal article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (11) , 1899-906
Abstract
Troponin T is an established marker of myocardial ischemia. We speculated that the role of the new high-sensitive troponin T (hs-cTnT) might expand towards non-ischemic myocardial disease, indicate disease severity and allow for prognostication in chronic heart failure. Hs-cTnT (Roche Diagnostics, Mannheim, Germany) was assessed in 233 individuals with chronic heart failure (n=149) or healthy controls (n=84). Hs-cTnT was significantly elevated in patients with chronic heart failure [0.018 ng/mL, interquartile range (IQR) 0.009-0.036 ng/mL, vs. controls 0.003 ng/mL, 0.003-0.003 ng/mL, p<0.001] and positively correlated with N-terminal pro-b-type natriuretic peptide (NT-proBNP) (r=0.79, p<0.001). Hs-cTnT increased stepwise and signitificantly according to clinical (NYHA stage) as well as functional (LV ejection fraction, fluid retention) severity (each p<0.001). At a binary cutpoint of 0.014 ng/mL, hs-TropT was a significant predictor of all-cause mortality and all-cause mortality or rehospitalization for congestive heart failure (each p≤0.01). Of note, the prognostic value of hs-TropT was independent and additive to that of NT-proBNP. Hs-cTnT increases stepwise with the severity of symptoms and LV dysfunction and offers important prognostic information in chronic heart failure, independently from and additive to NT-proBNP. The utility of hs-cTnT expands beyond acute myocardial ischemia and towards chronic heart failure.Keywords
This publication has 30 references indexed in Scilit:
- An Update on Cardiac Troponins as Circulating Biomarkers in Heart FailureCurrent Heart Failure Reports, 2010
- A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery DiseaseNew England Journal of Medicine, 2009
- Reference Population and Marathon Runner Sera Assessed by Highly Sensitive Cardiac Troponin T and Commercial Cardiac Troponin T and I AssaysClinical Chemistry, 2009
- Higher sensitivity troponin assays: Quo vadis?European Heart Journal, 2008
- Universal Definition of Myocardial InfarctionCirculation, 2007
- Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart FailureCirculation, 2007
- NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudyEuropean Heart Journal, 2006
- ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the AdultJACC, 2005
- N-Terminal Pro-Brain Natriuretic Peptide After Myocardial InfarctionHypertension, 2002
- Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairmentClinical Endocrinology, 1997